Andrea G Edlow1,2, Jonathan Z Li3, Ai-Ris Y Collier4,5, Caroline Atyeo6, Kaitlyn E James1, Adeline A Boatin1, Kathryn J Gray7, Evan A Bordt8, Lydia L Shook1, Lael M Yonker9, Alessio Fasano9, Khady Diouf7, Natalie Croul1, Samantha Devane9, Laura J Yockey1,10, Rosiane Lima9, Jessica Shui9, Juan D Matute9, Paul H Lerou9, Babatunde O Akinwunmi7, Aaron Schmidt6,11, Jared Feldman6, Blake M Hauser6, Timothy M Caradonna6, Denis De la Flor9, Paolo D'Avino9, James Regan3, Heather Corry3, Kendyll Coxen3, Jesse Fajnzylber3, David Pepin12, Michael S Seaman5, Dan H Barouch5,6, Bruce D Walker6, Xu G Yu6,10, Anjali J Kaimal1, Drucilla J Roberts13, Galit Alter6. 1. Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Harvard Medical School, Boston. 2. Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston. 3. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Obstetrics, Gynecology and Reproductive Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 5. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 6. Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, Massachusetts. 7. Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston. 9. Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston. 10. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. 11. Department of Microbiology, Harvard Medical School, Boston, Massachusetts. 12. Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston. 13. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
Importance: Biological data are lacking with respect to risk of vertical transmission and mechanisms of fetoplacental protection in maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective: To quantify SARS-CoV-2 viral load in maternal and neonatal biofluids, transplacental passage of anti-SARS-CoV-2 antibody, and incidence of fetoplacental infection. Design, Setting, and Participants: This cohort study was conducted among pregnant women presenting for care at 3 tertiary care centers in Boston, Massachusetts. Women with reverse transcription-polymerase chain reaction (RT-PCR) results positive for SARS-CoV-2 were recruited from April 2 to June 13, 2020, and follow-up occurred through July 10, 2020. Contemporaneous participants without SARS-CoV-2 infection were enrolled as a convenience sample from pregnant women with RT-PCR results negative for SARS-CoV-2. Exposures: SARS-CoV-2 infection in pregnancy, defined by nasopharyngeal swab RT-PCR. Main Outcomes and Measures: The main outcomes were SARS-CoV-2 viral load in maternal plasma or respiratory fluids and umbilical cord plasma, quantification of anti-SARS-CoV-2 antibodies in maternal and cord plasma, and presence of SARS-CoV-2 RNA in the placenta. Results: Among 127 pregnant women enrolled, 64 with RT-PCR results positive for SARS-CoV-2 (mean [SD] age, 31.6 [5.6] years) and 63 with RT-PCR results negative for SARS-CoV-2 (mean [SD] age, 33.9 [5.4] years) provided samples for analysis. Of women with SARS-CoV-2 infection, 23 (36%) were asymptomatic, 22 (34%) had mild disease, 7 (11%) had moderate disease, 10 (16%) had severe disease, and 2 (3%) had critical disease. In viral load analyses among 107 women, there was no detectable viremia in maternal or cord blood and no evidence of vertical transmission. Among 77 neonates tested in whom SARS-CoV-2 antibodies were quantified in cord blood, 1 had detectable immunoglobuilin M to nucleocapsid. Among 88 placentas tested, SARS-CoV-2 RNA was not detected in any. In antibody analyses among 37 women with SARS-CoV-2 infection, anti-receptor binding domain immunoglobin G was detected in 24 women (65%) and anti-nucleocapsid was detected in 26 women (70%). Mother-to-neonate transfer of anti-SARS-CoV-2 antibodies was significantly lower than transfer of anti-influenza hemagglutinin A antibodies (mean [SD] cord-to-maternal ratio: anti-receptor binding domain immunoglobin G, 0.72 [0.57]; anti-nucleocapsid, 0.74 [0.44]; anti-influenza, 1.44 [0.80]; P < .001). Nonoverlapping placental expression of SARS-CoV-2 receptors angiotensin-converting enzyme 2 and transmembrane serine protease 2 was noted. Conclusions and Relevance: In this cohort study, there was no evidence of placental infection or definitive vertical transmission of SARS-CoV-2. Transplacental transfer of anti-SARS-CoV-2 antibodies was inefficient. Lack of viremia and reduced coexpression and colocalization of placental angiotensin-converting enzyme 2 and transmembrane serine protease 2 may serve as protective mechanisms against vertical transmission.
Importance: Biological data are lacking with respect to risk of vertical transmission and mechanisms of fetoplacental protection in maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective: To quantify SARS-CoV-2 viral load in maternal and neonatal biofluids, transplacental passage of anti-SARS-CoV-2 antibody, and incidence of fetoplacental infection. Design, Setting, and Participants: This cohort study was conducted among pregnant women presenting for care at 3 tertiary care centers in Boston, Massachusetts. Women with reverse transcription-polymerase chain reaction (RT-PCR) results positive for SARS-CoV-2 were recruited from April 2 to June 13, 2020, and follow-up occurred through July 10, 2020. Contemporaneous participants without SARS-CoV-2 infection were enrolled as a convenience sample from pregnant women with RT-PCR results negative for SARS-CoV-2. Exposures: SARS-CoV-2 infection in pregnancy, defined by nasopharyngeal swab RT-PCR. Main Outcomes and Measures: The main outcomes were SARS-CoV-2 viral load in maternal plasma or respiratory fluids and umbilical cord plasma, quantification of anti-SARS-CoV-2 antibodies in maternal and cord plasma, and presence of SARS-CoV-2 RNA in the placenta. Results: Among 127 pregnant women enrolled, 64 with RT-PCR results positive for SARS-CoV-2 (mean [SD] age, 31.6 [5.6] years) and 63 with RT-PCR results negative for SARS-CoV-2 (mean [SD] age, 33.9 [5.4] years) provided samples for analysis. Of women with SARS-CoV-2 infection, 23 (36%) were asymptomatic, 22 (34%) had mild disease, 7 (11%) had moderate disease, 10 (16%) had severe disease, and 2 (3%) had critical disease. In viral load analyses among 107 women, there was no detectable viremia in maternal or cord blood and no evidence of vertical transmission. Among 77 neonates tested in whom SARS-CoV-2 antibodies were quantified in cord blood, 1 had detectable immunoglobuilin M to nucleocapsid. Among 88 placentas tested, SARS-CoV-2 RNA was not detected in any. In antibody analyses among 37 women with SARS-CoV-2 infection, anti-receptor binding domain immunoglobin G was detected in 24 women (65%) and anti-nucleocapsid was detected in 26 women (70%). Mother-to-neonate transfer of anti-SARS-CoV-2 antibodies was significantly lower than transfer of anti-influenza hemagglutinin A antibodies (mean [SD] cord-to-maternal ratio: anti-receptor binding domain immunoglobin G, 0.72 [0.57]; anti-nucleocapsid, 0.74 [0.44]; anti-influenza, 1.44 [0.80]; P < .001). Nonoverlapping placental expression of SARS-CoV-2 receptors angiotensin-converting enzyme 2 and transmembrane serine protease 2 was noted. Conclusions and Relevance: In this cohort study, there was no evidence of placental infection or definitive vertical transmission of SARS-CoV-2. Transplacental transfer of anti-SARS-CoV-2 antibodies was inefficient. Lack of viremia and reduced coexpression and colocalization of placental angiotensin-converting enzyme 2 and transmembrane serine protease 2 may serve as protective mechanisms against vertical transmission.
Authors: Sidney Ogolla; Ibrahim I Daud; Amolo S Asito; Odada P Sumba; Collins Ouma; John Vulule; Jaap M Middeldorp; Arlene E Dent; Saurabh Mehta; Rosemary Rochford Journal: Clin Vaccine Immunol Date: 2015-09-16
Authors: Elisheva D Shanes; Leena B Mithal; Sebastian Otero; Hooman A Azad; Emily S Miller; Jeffery A Goldstein Journal: Am J Clin Pathol Date: 2020-06-08 Impact factor: 2.493
Authors: Pradip Dashraath; Jing Lin Jeslyn Wong; Mei Xian Karen Lim; Li Min Lim; Sarah Li; Arijit Biswas; Mahesh Choolani; Citra Mattar; Lin Lin Su Journal: Am J Obstet Gynecol Date: 2020-03-23 Impact factor: 8.661
Authors: Maira L S Takemoto; Mariane de O Menezes; Carla B Andreucci; Marcos Nakamura-Pereira; Melania M R Amorim; Leila Katz; Roxana Knobel Journal: Int J Gynaecol Obstet Date: 2020-07-29 Impact factor: 4.447
Authors: Jonathon L Hecht; Bradley Quade; Vikram Deshpande; Mari Mino-Kenudson; David T Ting; Niyati Desai; Beata Dygulska; Taryn Heyman; Carolyn Salafia; Dejun Shen; Sara V Bates; Drucilla J Roberts Journal: Mod Pathol Date: 2020-08-02 Impact factor: 8.209
Authors: Yusuke Matsui; Lin Li; Mary Prahl; Arianna G Cassidy; Nida Ozarslan; Yarden Golan; Veronica J Gonzalez; Christine Y Lin; Unurzul Jigmeddagva; Megan A Chidboy; Mauricio Montano; Taha Y Taha; Mir M Khalid; Bharath Sreekumar; Jennifer M Hayashi; Pei-Yi Chen; G Renuka Kumar; Lakshmi Warrier; Alan Hb Wu; Dongli Song; Priya Jegatheesan; Daljeet S Rai; Balaji Govindaswami; Jordan Needens; Monica Rincon; Leslie Myatt; Ifeyinwa V Asiodu; Valerie J Flaherman; Yalda Afshar; Vanessa L Jacoby; Amy P Murtha; Joshua F Robinson; Melanie Ott; Warner C Greene; Stephanie L Gaw Journal: JCI Insight Date: 2022-06-22
Authors: Ann-Christin Tallarek; Christopher Urbschat; Luis Fonseca Brito; Stephanie Stanelle-Bertram; Susanne Krasemann; Giada Frascaroli; Kristin Thiele; Agnes Wieczorek; Nadine Felber; Marc Lütgehetmann; Udo R Markert; Kurt Hecher; Wolfram Brune; Felix Stahl; Gülsah Gabriel; Anke Diemert; Petra Clara Arck Journal: Front Immunol Date: 2021-06-03 Impact factor: 7.561
Authors: Dongli Song; Mary Prahl; Stephanie L Gaw; Sudha Rani Narasimhan; Daljeet S Rai; Angela Huang; Claudia V Flores; Christine Y Lin; Unurzul Jigmeddagva; Alan Wu; Lakshmi Warrier; Justine Levan; Catherine B T Nguyen; Perri Callaway; Lila Farrington; Gonzalo R Acevedo; Veronica J Gonzalez; Anna Vaaben; Phuong Nguyen; Elda Atmosfera; Constance Marleau; Christina Anderson; Sonya Misra; Monica Stemmle; Maria Cortes; Jennifer McAuley; Nicole Metz; Rupalee Patel; Matthew Nudelman; Susan Abraham; James Byrne; Priya Jegatheesan Journal: BMJ Open Date: 2021-07-07 Impact factor: 2.692
Authors: G R Scott Budinger; Alexander V Misharin; Karen M Ridge; Benjamin D Singer; Richard G Wunderink Journal: J Clin Invest Date: 2021-07-15 Impact factor: 19.456